



Resource impact statement

Resource impact

Published: 19 February 2020

www.nice.org.uk

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population).

This is because the technology is a further treatment option and has been commissioned by NHS England since 2015 for people with relapsing–remitting multiple sclerosis as a first-line treatment or as an alternative when other first-line treatments are not tolerated. Therefore, we do not think practice will change substantially as a result of this guidance.

Peginterferon beta-1a involves less frequent injections than other beta interferons, so improves choice for people with relapsing–remitting multiple sclerosis.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.